Our test BGaze TDAH validation study has been published in the Journal of Attention Disorders.
Braingaze closely collaborates with several academic hospitals to study and validate our biomarker of attention for the diagnosis of neurodevelopmental disorders.
As a results of these collaborations, Paloma Varela, child and adolescent psychiatrist and Dr. José Cañete, director of the Dept. of Child and Adolescent Psychiatry of the Hospital Mataró, in collaboration with Prof. Dr. Stephen Faraone, of the Upstate Medical University of New York and Prof. Dr. Josep Antoni Ramos-Quiroga, head of the Dept. Psychiatry of the University Hospital Vall d ‘Hebron have been working on the validation of the BGaze biomarker for ADHD in children between 7-14 years of age.
Children with attentional and conduct problems were evaluated with the BGaze test and the results have been compared between ADHD patients, clinical controls and healthy subjects .The results demonstrate a high classification accuracy of the BGaze marker with low false positive and false negatives rates.
The validation study shows that the BGaze test is a reliable and objective tool supporting clinical diagnosis of AHD in children.
The article describing the validation study can be downloaded here
Ever since Braingaze started to work with child and adult psychiatrists that frequently diagnose ADHD, we have been asked if our unique patented technology could also be applied to the diagnosis of other cognitive disorders.
Recently we validated in collaboration with the Binding Project (website only in Spanish or Catalan) our 5mn dyslexia test involving some 250 subjects. Within the validation study, in more than 9 out of 10 cases our 5mn self-executed test score was less than one score point apart from the gold standard test score (which quantifies dyslexia level on a scale of 0 to 5, requiring a specialist psychologist to administer the test). This exceptional performance goes beyond a simple yes/no answer to dyslexia risk – it truly quantifies with a quite acceptable accuracy the level and nature of reading problems a subject has. And as with our ADHD test, the neuromarker eye movement we measure are involuntary, impossible to fake and do not depend on state of mind, motivation or stress levels.
Braingaze is presently making the dyslexia check available to the tens of very highly regarded clinics that already have adopted the BGaze platform. These clinics can from now on use the BGaze system to run and report on 3 tests: child ADHD, adult ADHD and dyslexia check, all using one single set-up at the psychiatrist clinic without need for referral to other specialized clinics.
Any clinic adopting the BGaze system before the end of this year will also be able to take advantage of this launch offer: for the same initial system investment, you get all three Bgaze tests (Child ADHD, Adult ADHD and Dyslexia) included in the system, ready for use in daily clinical practice.
It may sound strange that one biomarker eye movement can be used to detect the presence of various cognitive disorders. The key is that BGaze uses a very specific visual task for each disorder that it tests for. So while for ADHD our visual task is about the modulation of cognitive attention in an unpredictable task, the tasks we use to detect dyslexia are about cognitive attention levels used to recognize and interpret words shown on screen. In the game package we have developed for autism (which is presently being validated with various international experts on that disorder) the visual stimuli games are related to recognition of facial expressions, emotional response and similar visual tasks that trigger cognitive processes that are specific for a certain disorder.
Prof Dr J. Antoni Ramos-Quiroga, head of the psychiatry department at the Vall d’Hebron University Hospital and president of its Innovation Commission chairs our Advisory Board. He is Associate Professor of Psychiatry at the Universitat Autònoma de Barcelona. He is principal investigator of the Vall d’Hebron University Hospital. He conducts research focused on ADHD in adolescents and adults, including clinical trials, drug trials, studies of neuroimaging and genetics. He is author of more than 100 international publications and several books on ADHD.
Prof Dr Susan Young joins as well, she is Clinical Senior Lecturer in Forensic Clinical Psychology in the Centre for Mental Health at the Imperial College of London; President of the UK ADHD Partnership and Vice President of the UK Adult ADHD Network. She’s also the author of the globally used ACE and ACE+ Clinical Interviews and as such has contributed to structuring the ADHD diagnostic practice in over 20 countries. Braingaze will make these Clinical Interviews available soon as mobile internet enabled online functionality.
And last but not least, we welcome Alexandre Perera I Lluna, PhD. He is a physicist and an electrical engineer. He is an Associate Professor at the Politecnical University of Catalonia, and he is also a researcher at Sant Joan de Déu Research Foundation (Paediatric Research Institute in Barcelona area). Alexandre has published over 40 peer-reviewed articles in indexed journals and issued five patents. His main area of expertise covers machine learning, statistical analysis, and data mining in biomedical systems, bioengineering and bioinformatics. He currently leads the Bioinformatics and Biomedical Signals Lab at the Politechnical University of Catalonia.
TDAH Vallès not only provides care and assistance, but it organizes various activities aimed at training, providing information, and dissemination of ADHD and other neurodevelopmental disorders that cause learning difficulties in children. Therefore the III National Congress on Individual Differences and Specific Educational Needs focuses on school failure.
Braingaze is now formally member of the Mental Health Cluster of Catalonia. This cluster offers people with mental illnesses and their families a space where research, teaching and treatment of these pathologies converge. The Mental Health Cluster is considered as a geographic concentration of companies, services and interconnected institutions that share the strategic challenges of assistance, training, research and the creation of synergies.
At the CORE Salut Mental event people will discuss and showcase latest technology and innovations which are implemented in the Mental Health area. Novel potential tools discussed are optogenetics, deep brain stimulation, big data, virtual reality. In the demo session Braingaze wil demonstrate the objective diagnostic tool BGaze.